Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neuroblastoma 7Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Temozolomide 6Cyclophosphamide 5cabozantinib 4Vincristine 4fludarabine 3Radiotherapy 3Irinotecan 3liposomal doxorubicin 2irinotecan sucrosofate 2Zoledronic Acid 2Topotecan 2Specimen Handling 2PM 01183 2Ifosfamide 2Etoposide 2Eflornithine 2Drug Therapy 2Doxorubicin 2trilaciclib 1trifluridine tipiracil drug combination 1talazoparib 1silmitasertib 1romiplostim 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1naxitamab 1fluzoparib 1fludarabine phosphate 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Ewing × naxitamab × Clear all
NCT05968768 2025-04-10

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Institute of Mother and Child, Warsaw, Poland

Phase 2 Recruiting
24 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡